Erbitux Cetuximab
Trademark details
Erbitux Cetuximab® is a registered trademark used for Pharmaceutical Preparation, Namely Monoclonal Antibody For the Treatment of Cancer and owned by ImClone Systems Incorporated. Full trade mark registration details, registered images and more information below.
| Goods and/or Services: | Pharmaceutical Preparation, Namely Monoclonal Antibody For the Treatment of Cancer |
| Serial Number: | 76670452 |
| Registration Number: | 3333263 |
| Filing Date: | Dec 18, 2006 |
|
Last Applicant(s)/ Owner(s) of Record | ImClone Systems Incorporated180 Varick Street |
| Related Products: | Pharmaceuticals |
Web Sites
powered by 
Total : 191,000 View more »
Head and Neck Cancer | Colorectal Cancer | ERBITUX (cetuximab)
Head and Neck Cancer | Colorectal Cancer | ERBITUX (cetuximab)
Cetuximab - Wikipedia, the free encyclopedia
Cetuximab (Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous infusion for treatment ...
Metastatic Colorectal Cancer | ERBITUX (cetuximab)
ERBITUX ® (cetuximab) ERBITUX ® (cetuximab) is indicated for the treatment of patients who have colorectal cancer that has spread to other parts of the body and ...
Cetuximab - National Cancer Institute - Comprehensive Cancer ...
US Brand Name(s): Erbitux: FDA Approved: Yes ... Cetuximab is also being studied in the treatment of other types of cancer.
Web Sites
Total : 1 View more »
In Vitro Companion Diagnostic Devices
...cells. EGFR pharmDx is indicated as an aid in identifying colorectal cancer patients eligible for treatment with Erbitux (cetuximab) or Vectibix (panitumumab).td> 8 DAKO C-KIT PharmDx P040011 S001 Dako North America, Inc...
News and Blogs
Total : 36 View more »
Idera Pharmaceuticals Inc s IMO 2055 Dissapoints
...the Company’s investigational oncology product candidate targeting Toll-like Receptor 9 in combination with Erbitux® (cetuximab) for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in...
Personalized Medicine Market -Advances in Human Genomics and Proteomics to Challenge Traditional The
...include Herceptin (trastuzumab) , Gleevec (imatinib), Coumadin (warfarin), Camptosar (irinotecan) and Erbitux (cetuximab). Herceptin, for instance, is used to treat breast cancer patients that over-express...
Delays give patients no option: Merck | Australian Doctor
...the PBS despite being recommended for listing by the Federal Government’s expert drug committee 10 months ago. Erbitux (cetuximab), which costs about $2000 per week per patient, was recommended by the Pharmaceutical Benefits Advisory Committee...
australiandoctor.com.au
...breast cancer doesn’t have overactive HER2 receptors, the drug will have no beneficial effect. Another drug, Erbitux (cetuximab), is useful for the approximately 75% of metastatic colorectal cancer patients whose tumors express another receptor...
